Gilead Sciences Inc. entered into an Agreement and Plan of Merger (the Merger Agreement) among . parent CymaBay Therapeutics Inc. a Delaware corporation (the Company) and a wholly-owned subsidiary of Parent (Purchaser). Purchaser will commence a tender offer to purchase all of the issued and outstanding shares of the Company at a price of $32.50 per share. The Offer will initially remain open for a minimum of 20 business days from the date of commencement of the Offer . If at the scheduled expiration time of the offer any of the conditions have not been satisfied, it will be extended. The offer will not be terminated immediately. The Company will pay a termination fee of $1516.00 per Share (or any other direct or indirect wholly owned subsidiary of the Parent or Purchaser).

Woman in front of the Computer
Photo by Mikael Blomkvist courtesy Pexels


Price Summary

The price of CymaBay Therapeutics opened at 31.89 in the expected range due to the offer. The price of Gilead Sciences, Inc. opened at 73.41 and closed at 74.45 on 2024-02-12 with a low of 73.11 and a high of 75.14. The volume for the stock was 7604600.

The highest price for the 52-week period for the stock is 87.29 and the lowest price over the same period is 73.27.

Recommendations from 24 analysts put the price expectation for GILD to range between 69.0 and 116.0. The mean price expectation is about 87.54.

Technicals

The current price of 74.45 finds support at 74.24 and resistance at 75.62. The recent price move is breaching resistance.

GILD supportResistance 091ead
Support/Resistance for GILD


The PSAR continues its bearish outlook and sets a level of resistance.

GILD psar 091ead
Parabolic Stop and Reverse chart for Gilead Sciences, Inc.


The K-line is above the D-line on stochastic and the K-line is below 20. This is generally considered to be the start of a bullish move.

GILD stoch 091ead
Stochastic chart for Gilead Sciences, Inc.